Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease

NCT00269854 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.

NCT NCT00269854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00269854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease
Lead sponsor
Centocor, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
June 30, 1995
Completion date
October 31, 1996
Enrollment
108 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease